| A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality RK Wadhera, DL Steen, I Khan, RP Giugliano, JAM Foody Journal of clinical lipidology 10 (3), 472-489, 2016 | 381 | 2016 |
| Quantifying importance of major risk factors for coronary heart disease MJ Pencina, AM Navar, D Wojdyla, RJ Sanchez, I Khan, J Elassal, ... Circulation 139 (13), 1603-1611, 2019 | 215 | 2019 |
| Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease CP Cannon, I Khan, AC Klimchak, MR Reynolds, RJ Sanchez, WJ Sasiela JAMA cardiology 2 (9), 959-966, 2017 | 161 | 2017 |
| The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability RS Rosenson, K Miller, M Bayliss, RJ Sanchez, MT Baccara-Dinet, ... Cardiovascular Drugs and Therapy 31, 179-186, 2017 | 130 | 2017 |
| Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults … ND Wong, D Young, Y Zhao, H Nguyen, J Caballes, I Khan, RJ Sanchez Journal of clinical lipidology 10 (5), 1109-1118, 2016 | 102 | 2016 |
| Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk … T Teramoto, K Uno, I Miyoshi, I Khan, K Gorcyca, RJ Sanchez, S Yoshida, ... Atherosclerosis 251, 248-254, 2016 | 65 | 2016 |
| Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands JG Kuiper, RJ Sanchez, E Houben, EM Heintjes, FJA Penning-van Beest, ... Clinical Therapeutics 39 (4), 819-827. e1, 2017 | 51 | 2017 |
| Patterns and predictors of lipid‐lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: insights from a large US managed … DL Steen, I Khan, L Becker, JAM Foody, K Gorcyca, RJ Sanchez, ... Clinical cardiology 40 (3), 155-162, 2017 | 47 | 2017 |
| Evaluation of mortality data from the social security administration death master file for clinical research AM Navar, ED Peterson, DL Steen, DM Wojdyla, RJ Sanchez, I Khan, ... JAMA cardiology 4 (4), 375-379, 2019 | 45 | 2019 |
| Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care … DL Steen, I Khan, D Ansell, RJ Sanchez, KK Ray BMJ open 7 (2), e013255, 2017 | 43 | 2017 |
| Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during … DL Steen, I Khan, K Andrade, A Koumas, RP Giugliano Journal of the American Heart Association 11 (9), e022198, 2022 | 39 | 2022 |
| Association of cinacalcet adherence and costs in patients on dialysis A Lee, X Song, I Khan, V Belozeroff, W Goodman, N Fulcher, D Diakun Journal of medical economics 14 (6), 798-804, 2011 | 36 | 2011 |
| Application of the statin-associated muscle symptoms-clinical index to a randomized trial on statin myopathy BA Taylor, RJ Sanchez, TA Jacobson, D Chibedi-De-Roche, G Manvelian, ... Journal of the American College of Cardiology 70 (13), 1680-1681, 2017 | 34 | 2017 |
| Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008 DM Spiegel, I Khan, M Krishnan, TJ Mayne American journal of kidney diseases 55 (1), 113-120, 2010 | 25 | 2010 |
| Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population A Sharma, J Yee, SR Gandra, I Khan, J Petersen Current medical research and opinion 26 (11), 2679-2687, 2010 | 19 | 2010 |
| Simulation of the impact of statin intolerance on the need for ezetimibe and/or proprotein convertase subtilisin/kexin type 9 inhibitor for meeting low-density lipoprotein … CP Cannon, RJ Sanchez, AC Klimchak, I Khan, WJ Sasiela, MR Reynolds, ... The American Journal of Cardiology 123 (8), 1202-1207, 2019 | 17 | 2019 |
| Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease CP Cannon, I Khan, AC Klimchak, RJ Sanchez, WJ Sasiela, JM Massaro, ... American Heart Journal 216, 30-41, 2019 | 15 | 2019 |
| Risk of cardiovascular events in patients with type 2 diabetes and metabolic dyslipidemia without prevalent atherosclerotic cardiovascular disease JS Rana, JY Liu, HH Moffet, RJ Sanchez, I Khan, AJ Karter The American journal of medicine 133 (2), 200-206, 2020 | 14 | 2020 |
| Prevalence of atherosclerotic cardiovascular disease (ASCVD) and diabetes populations in the United States K Gorcyca, I Khan, R Wadhera, A Klimchak, X Song, R Sanchez, K Gooch Journal of Clinical Lipidology 9 (3), 424, 2015 | 14 | 2015 |
| Calibration and Uncertainty in Neural Time-to-Event Modeling P Chapfuwa, C Tao, C Li, I Khan, KJ Chandross, MJ Pencina, L Carin, ... IEEE Transactions on Neural Networks and Learning Systems 34 (4), 1666-1680, 2023 | 12 | 2023 |
Robert J SanchezRegeneron在 regeneron.com 的电子邮件经过验证
